About Chembio Diagnostics (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
Industry, Sector and Symbol:
- Industry: Diagnostic & Testing Substances Manufacturers
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:CEMI
- CUSIP: N/A
- Web: www.chembio.com
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 3.54%
- Quick Ratio: 2.19%
Sales & Book Value:
- Annual Sales: $17.87 million
- Price / Sales: 4.65
- Book Value: $1.21 per share
- Price / Book: 5.58
- Trailing EPS: ($0.57)
- Net Income: ($13,340,000.00)
- Net Margins: -32.42%
- Return on Equity: -42.76%
- Return on Assets: -34.54%
- Employees: 131
- Outstanding Shares: 12,320,000
Frequently Asked Questions for Chembio Diagnostics (NASDAQ:CEMI)
What is Chembio Diagnostics' stock symbol?
Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
How were Chembio Diagnostics' earnings last quarter?
Chembio Diagnostics, Inc. (NASDAQ:CEMI) issued its earnings results on Thursday, August, 11th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.75. The firm earned $3.27 million during the quarter, compared to the consensus estimate of $6.72 million. Chembio Diagnostics had a negative net margin of 32.42% and a negative return on equity of 42.76%. View Chembio Diagnostics' Earnings History.
Who are some of Chembio Diagnostics' key competitors?
Some companies that are related to Chembio Diagnostics include Concord Medical Services Holdings Limited (CCM), Fate Therapeutics (FATE), Signal Genetics (MGEN), Otonomy (OTIC), Cidara Therapeutics (CDTX), Pluristem Therapeutics (PSTI), Merrimack Pharmaceuticals (MACK), Mirna Therapeutics (SYBX), Ocular Therapeutix (OCUL), Verona Pharma PLC American Depositary Share (VRNA), Summit Therapeutics PLC (SMMT), XBiotech (XBIT), Cellular Biomedicine Group (CBMG), iRadimed Corporation (IRMD), ConforMIS (CFMS), Invuity (IVTY), Genesis Healthcare (GEN) and DURECT Corporation (DRRX).
Who are Chembio Diagnostics' key executives?
Chembio Diagnostics' management team includes the folowing people:
- John J. Sperzel III, President, Chief Executive Officer, Director (Age 52)
- Richard J. Larkin, Chief Financial Officer (Age 58)
- Sharon Klugewicz, President - Americas Region (Age 49)
- Javan Esfandiari, Chief Science and Technology Officer (Age 48)
- Tom Ippolito, Vice President - Regulatory Affairs, Quality Assurance and Quality Control (Age 52)
- Paul Lambotte Ph.D., Vice President - Product Development (Age 64)
- Michael K. Steele, Vice President - Business Development, Sales and Marketing (Age 48)
- Katherine L. Davis, Non-Executive Independent Chairman of the Board (Age 58)
- Gail S. Page, Director
- Peter T. Kissinger Ph.D., Independent Director (Age 70)
Who owns Chembio Diagnostics stock?
Chembio Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (0.29%) and Benchmark Capital Advisors (0.27%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, Norman H Pessin and Sharon W Klugewicz. View Institutional Ownership Trends for Chembio Diagnostics.
Who sold Chembio Diagnostics stock? Who is selling Chembio Diagnostics stock?
Who bought Chembio Diagnostics stock? Who is buying Chembio Diagnostics stock?
How do I buy Chembio Diagnostics stock?
Shares of Chembio Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chembio Diagnostics' stock price today?
One share of Chembio Diagnostics stock can currently be purchased for approximately $6.75.
How big of a company is Chembio Diagnostics?
Chembio Diagnostics has a market capitalization of $84.38 million and generates $17.87 million in revenue each year. The company earns ($13,340,000.00) in net income (profit) each year or ($0.57) on an earnings per share basis. Chembio Diagnostics employs 131 workers across the globe.
How can I contact Chembio Diagnostics?
MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at firstname.lastname@example.org.
Analysts' Consensus Ratings for Chembio Diagnostics (NASDAQ:CEMI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|Consensus Price Target History for Chembio Diagnostics (NASDAQ:CEMI)
Analysts' Ratings History for Chembio Diagnostics (NASDAQ:CEMI)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/11/2016||Benchmark Co.||Set Price Target||Buy||$9.00||N/A|
Earnings History for Chembio Diagnostics (NASDAQ:CEMI)Earnings History by Quarter for Chembio Diagnostics (NASDAQ CEMI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.17)||($0.18)||$4.96 million||$2.89 million||View||Listen|
|5/9/2017||Q1 2017||($0.20)||($0.13)||$4.88 million||$5.43 million||View||Listen|
|3/7/2017||Q4 2016||($0.15)||($0.21)||$4.44 million||$4.26 million||View||Listen|
|11/10/2016||Q3 2016||($0.17)||($0.19)||$3.76 million||$3.75 million||View||N/A|
|8/11/2016||Q2||($0.11)||($0.86)||$6.72 million||$3.27 million||View||Listen|
|5/12/2016||Q1||($0.09)||($0.03)||$4.83 million||$6.60 million||View||Listen|
|3/8/2016||Q4||($0.09)||($0.07)||$6.56 million||$4.42 million||View||N/A|
|11/12/2015||Q3||($0.09)||($0.05)||$6.77 million||$6.89 million||View||Listen|
|8/6/2015||Q2||($0.03)||($0.07)||$7.53 million||$6.72 million||View||N/A|
|5/7/2015||Q115||($0.08)||($0.07)||$5.20 million||$6.20 million||View||N/A|
|3/5/2015||Q414||($0.04)||($0.05)||$7.10 million||$7.10 million||View||N/A|
|11/6/2014||Q3 2014||($0.03)||($0.03)||$7.71 million||$7.31 million||View||N/A|
|8/7/2014||Q2||($0.02)||($0.02)||$6.25 million||$7.42 million||View||N/A|
|5/8/2014||Q1 2014||($0.02)||($0.02)||$6.87 million||$5.81 million||View||N/A|
|3/6/2014||Q413||$0.04||($0.03)||$7.05 million||$7.86 million||View||N/A|
|8/8/2013||Q2 2013||($0.04)||($0.03)||$5.56 million||$5.39 million||View||N/A|
|11/13/2012||Q312||$0.04||($0.04)||$6.11 million||$5.01 million||View||N/A|
Earnings Estimates for Chembio Diagnostics (NASDAQ:CEMI)
2017 EPS Consensus Estimate: ($0.55)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Chembio Diagnostics (NASDAQ:CEMI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Chembio Diagnostics (NASDAQ CEMI)
Insider Ownership Percentage: 5.56%Insider Trades by Quarter for Chembio Diagnostics (NASDAQ CEMI)
Institutional Ownership Percentage: 30.57%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/28/2017||Norman H Pessin||Insider||Buy||36,250||$5.48||$198,650.00|| |
|6/15/2016||Sharon W Klugewicz||COO||Sell||3,000||$8.40||$25,200.00|| |
|6/1/2016||Javan Esfandiari||Insider||Sell||25,000||$8.58||$214,500.00|| |
|5/29/2015||Javan Esfandiari||Insider||Sell||20,000||$4.50||$90,000.00|| |
|11/19/2014||Peter Kissinger||Director||Buy||1,800||$4.31||$7,758.00|| |
|2/26/2014||Sharon W Klugewicz||COO||Buy||10,000||$3.50||$35,000.00|| |
|12/6/2013||Javan Esfandiari||SVP||Sell||10,000||$3.40||$34,000.00|| |
|11/11/2013||Lawrence A Siebert||Major Shareholder||Sell||30,000||$3.63||$108,900.00|| |
Headline Trends for Chembio Diagnostics (NASDAQ:CEMI)
Latest Headlines for Chembio Diagnostics (NASDAQ CEMI)
|Edited Transcript of CEMI earnings conference call or presentation 8-Nov-17 9:30pm GMT|
finance.yahoo.com - November 9 at 7:55 PM
|ETFs with exposure to Chembio Diagnostics, Inc. : November 9, 2017|
finance.yahoo.com - November 9 at 7:55 PM
|CHEMBIO DIAGNOSTICS, INC. to Host Earnings Call|
finance.yahoo.com - November 8 at 8:42 PM
|Chembio Diagnostics Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 8 at 8:42 PM
|Investor Network Invites You to the Chembio 2017 Third Quarter Earnings Conference Call and Webcast Live on Wednesday, November 8, 2017|
finance.yahoo.com - November 7 at 8:03 PM
|Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results|
feeds.benzinga.com - November 1 at 9:28 AM
|ETFs with exposure to Chembio Diagnostics, Inc. : October 30, 2017|
finance.yahoo.com - October 30 at 3:41 PM
|ETFs with exposure to Chembio Diagnostics, Inc. : October 17, 2017|
finance.yahoo.com - October 17 at 5:50 PM
|ETFs with exposure to Chembio Diagnostics, Inc. : October 5, 2017|
finance.yahoo.com - October 5 at 11:39 AM
|Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017|
finance.yahoo.com - October 4 at 12:24 PM
|Chembio Announces Return of President and CEO John Sperzel|
www.nasdaq.com - October 3 at 2:13 AM
|Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test|
finance.yahoo.com - October 2 at 4:09 PM
|BRIEF-Chembio Diagnostics says CFO Richard Larkin to retire by Dec 31|
www.reuters.com - August 17 at 11:24 PM
|Chembio Diagnostics (CEMI) CFO to Retire|
www.streetinsider.com - August 17 at 6:23 PM
|Chembio Diagnostics Announces Retirement of Chief Financial Officer|
finance.yahoo.com - August 17 at 6:23 PM
|Chembio Diagnostics' (CEMI) CEO John Sperzel on Q2 2017 Results - Earnings Call Transcript|
seekingalpha.com - August 11 at 5:29 PM
|Chembio Diagnostics, Inc. (CEMI) Posts Earnings Results, Misses Expectations By $0.02 EPS|
www.americanbankingnews.com - August 10 at 9:28 PM
|Edited Transcript of CEMI earnings conference call or presentation 9-Aug-17 8:30pm GMT|
finance.yahoo.com - August 10 at 6:15 PM
|Chembio Diagnostics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 9 at 5:16 PM
|Investor Network Invites You to the Chembio 2017 Second Quarter Earnings Conference Call and Webcast Live on Wednesday, August 9, 2017|
finance.yahoo.com - August 8 at 4:49 PM
|Chembio to Host Conference Call to Discuss Second Quarter 2017 Financial Results|
finance.yahoo.com - August 3 at 6:35 PM
|Gail S. Page Joins Chembio Diagnostics Board of Directors|
finance.yahoo.com - July 6 at 6:19 PM
|Chembio Diagnostics (CEMI) DPP Zika System Plus DPP Micro Reader Granted Approval by Brazilian Health Regulatory Agency|
www.streetinsider.com - July 5 at 10:53 PM
|Chembio’s DPP® Zika System Including the DPP® Micro Reader Approved by Brazil’s Health Regulatory Agency|
finance.yahoo.com - July 5 at 5:49 PM
|Chembio Diagnostics (CEMI) Diagnostics Announces $21.2M At-The-Market Program|
www.streetinsider.com - June 27 at 9:31 PM
|Chembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2017 Results - Earnings Call Transcript|
seekingalpha.com - May 10 at 4:24 PM
|CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 7 at 4:16 PM
|Q4 2016 Chembio Diagnostics Inc Earnings Release - After Market Close|
biz.yahoo.com - March 7 at 12:28 PM
|CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - February 28 at 4:27 PM
|Form 8-K CHEMBIO DIAGNOSTICS, For: Jan 27|
www.streetinsider.com - January 29 at 2:25 AM
|ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study|
www.rttnews.com - January 18 at 3:03 AM
|2:06 pm Chembio Diagnostics amends the terms of its previously announced stock purchase agreement with RVR Diagnostics|
us.rd.yahoo.com - December 13 at 4:53 PM
|CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - November 9 at 10:36 PM
|Chembio Diagnostics (CEMI) to Acquire RVR Diagnostics|
www.streetinsider.com - November 6 at 8:57 AM
|PTN Surges On Trial Data, PFE Dumps Cholesterol Drug, Watch Out For PRTA|
www.rttnews.com - November 2 at 10:26 AM
|ADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal|
www.nasdaq.com - September 29 at 9:03 AM
|Chembio Diagnostics (CEMI) Awarded CDC Contract for Zika, Dengue, and Chikungunya Surveillance|
www.streetinsider.com - September 29 at 9:03 AM
|Chembio Diagnostics (CEMI) Receives USDA Grant for Bovine TB POC Diagnostic Test Development|
www.streetinsider.com - September 26 at 4:24 PM
Chembio Diagnostics (NASDAQ CEMI) Chart for Friday, November, 17, 2017